Adilia Hormigo

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities
    Adilia Hormigo
    Department of Neurology, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY 10021, USA
    Arch Neurol 61:362-5. 2004
  2. ncbi Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment
    Adilia Hormigo
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 126:202-8. 2004
  3. ncbi YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas
    Adilia Hormigo
    Clinical Laboratories, Neurosurgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 12:5698-704. 2006
  4. pmc Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1244-51. 2011
  5. doi Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 105:607-12. 2011
  6. doi YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
    Andreas F Hottinger
    Brain Tumor Center, New York, NY, USA
    Ann Neurol 70:163-9. 2011
  7. pmc Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma
    Jennifer L Clarke
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
    J Clin Oncol 27:3861-7. 2009
  8. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
  9. pmc Prominin 1/CD133 endothelium sustains growth of proneural glioma
    Bi Sen Ding
    Ansary Stem Cell Institute, and Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
    PLoS ONE 8:e62150. 2013
  10. ncbi Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4570-4. 2006

Collaborators

Detail Information

Publications18

  1. ncbi Nonconvulsive status epilepticus in patients with cancer: imaging abnormalities
    Adilia Hormigo
    Department of Neurology, Memorial Sloan Kettering Cancer Center, and Weill Medical College of Cornell University, New York, NY 10021, USA
    Arch Neurol 61:362-5. 2004
    ..Convulsive status epilepticus may cause reversible neuroimaging abnormalities. These cortical changes have been reported rarely in association with nonconvulsive status epilepticus...
  2. ncbi Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment
    Adilia Hormigo
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 126:202-8. 2004
    ..Patients whose ocular disease was identified and treated before CNS progression had a significantly improved survival...
  3. ncbi YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas
    Adilia Hormigo
    Clinical Laboratories, Neurosurgical Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Cancer Res 12:5698-704. 2006
    ..We obtained prospective longitudinal serum samples from patients with gliomas to determine whether YKL-40 or MMP-9 could be used as serum markers...
  4. pmc Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 13:1244-51. 2011
    ..4, P< .0001). Longitudinal increases in serum YKL-40 are associated with increased risk of death in patients with glioblastomas and anaplastic gliomas. YKL-40 is also a putative indicator of disease status in these patients...
  5. doi Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas
    Fabio M Iwamoto
    The Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Neurooncol 105:607-12. 2011
    ..Changes in serum MMP-9 were not associated with survival in the anaplastic glioma cohort. Serum MMP-9 showed no utility in determining glioma disease status and was not a clinically relevant prognostic marker of survival...
  6. doi YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma
    Andreas F Hottinger
    Brain Tumor Center, New York, NY, USA
    Ann Neurol 70:163-9. 2011
    ..To evaluate YKL-40 and MMP-9 proteins as tumor biomarkers in serum samples from patients with primary central nervous system lymphoma (PCNSL)...
  7. pmc Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma
    Jennifer L Clarke
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY10065, USA
    J Clin Oncol 27:3861-7. 2009
    ..The goal of this randomized phase II study was to evaluate two different temozolomide regimens in the adjuvant treatment of newly diagnosed GBM...
  8. pmc Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Antonio Omuro
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Neuro Oncol 15:242-50. 2013
    ..In this phase II trial, we investigated the efficacy of a metronomic temozolomide schedule in the treatment of recurrent malignant gliomas (MGs)...
  9. pmc Prominin 1/CD133 endothelium sustains growth of proneural glioma
    Bi Sen Ding
    Ansary Stem Cell Institute, and Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA
    PLoS ONE 8:e62150. 2013
    ..These factors may support proneural tumor progression and could be potential targets for anti-angiogenic therapy...
  10. ncbi Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma
    Igor T Gavrilovic
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4570-4. 2006
    ..The purpose of this report is to update the initial results and provide long-term data regarding overall survival, patterns of relapse, and the risk of treatment-related neurotoxicity...
  11. doi Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Neurooncol 88:293-8. 2008
    ..To assess the frequency of chromosomes 1p and 19q deletions in gliomas and to correlate 1p deletion with prognosis in patients with grade 2 and grade 3 gliomas independently of histologic subtype...
  12. ncbi Treatment of primary central nervous system lymphoma
    Lisa M DeAngelis
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 31:684-92. 2004
    ..Consequently, the role of radiotherapy remains to be clarified in newly diagnosed younger patients with PCNSL...
  13. pmc Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers
    Adilia Hormigo
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 11:6-8. 2007
    ....
  14. pmc Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice
    Sergey V Shmelkov
    1 Howard Hughes Medical Institute, Ansary Stem Cell Institute and Department of Genetic Medicine, Weill Cornell Medical College, New York, New York, USA 2 These authors contributed equally to this work
    Nat Med 16:598-602, 1p following 602. 2010
    ..Thus, our studies identify Slitrk5 as an essential molecule at corticostriatal synapses and provide a new mouse model of OCD-like behaviors...
  15. doi Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review
    Elena Pentsova
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    J Neurooncol 106:15-21. 2012
    ....
  16. ncbi Primary ocular lymphoma: clinical features, diagnosis, and treatment
    Adilia Hormigo
    Department of Neurology, New York Presbyterian Hospital and Weill College of Medicine of Cornell University, New York, USA
    Clin Lymphoma 4:22-9. 2003
    ..The current treatment options are discussed. Although advances have been made, the optimal treatment for primary ocular lymphoma remains to be identified..
  17. ncbi A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
    Fabio M Iwamoto
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, 10021, USA
    J Neurooncol 87:85-90. 2008
    ..To investigate the efficacy and safety of the combination of vinorelbine and intensive temozolomide for recurrent or progressive brain metastases from solid tumors...
  18. pmc CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors
    Sergey V Shmelkov
    Howard Hughes Medical Institute, Ansary Center for Stem Cell Therapeutics, and Department of Genetic Medicine, Weill Medical College of Cornell University, New York, New York, USA
    J Clin Invest 118:2111-20. 2008
    ....